{"title":"Randomized Trials in Primary Care: Becoming Pragmatic","authors":"M. Marino, J. Heintzman","doi":"10.1370/afm.2832","DOIUrl":null,"url":null,"abstract":"society, but has also reminded us anew of the limitations and challenges of our scientific approaches. Take the example of randomized trials. While multiple randomized trials were demonstrating the efficacy and safety of SARSCoV-2 vaccines,1 it became clear that other interventions against SARS-CoV-2 (eg, community masking, physical distancing, school closures, national lockdowns, etc) required research paradigms outside of the classic randomized trial design to which many scientists are accustomed.2,3 This again reminds us that randomized trials may have significant practical limitations to their generalizability because they are in tightly controlled settings with narrow eligibility, and therefore often in settings divorced from the real world.4 Whereas classic randomized trials evaluate interventions in ideal settings, pragmatic trials evaluate interventions against real-world alternatives provided in routine care (especially in primary care). Typically, pragmatic trials also relax eligibility criteria which may allow for greater generalizability of study findings. With the benefit of generalizability, however, comes challenges that are unique to pragmatic trials. To balance the relative risks and benefits of both of these designs, investigators employ strategies that often hybridize the 2 designs to maximize benefit and minimize limitation. In this issue, 3 studies demonstrate increasingly used approaches to construct trials that are pragmatic, but retain features and benefits of classic trial design. First, a randomized controlled trial led by Mitchell et al5 sought to evaluate the relative effectiveness of additions to a nationally disseminated readmission reduction program (called Re-Engineered Discharge [RED]) to reduce hospital readmission rates and emergency department visits among depressed patients. In intent-to-treat (ITT) analyses, the study found no difference in all-cause hospitalization between the study arms. Intent-to-treat analyses are used in trials to account for real-word deviation from treatment, and include all randomized study participants in prespecified analyses regardless of events after they are randomized (eg, noncompliance, study withdrawal, protocol deviation, etc). Intent-to-treat analyses are thought to produce less bias than when the randomized participants who were entirely adherent to their assigned intervention are included in this analysis.6 An alternative to an intent-to-treat analysis is to consider as-treated analyses which compares intervention groups that only include patients who actually received the treatment(s) without regard to their randomized assignment.6 In addition to intent-to-treat analyses, Mitchell et al5 also performed as-treated analyses and found that with sufficient uptake of the adapted RED intervention, patients saw a larger decrease in hospital readmission compared with RED alone. While it is tempting to consider the as-treated analysis a definitive analysis, it is known that as-treated analyses are more likely to be biased and exaggerate treatment effects.6 In real-world settings, complete adherence to any intervention is a challenge. Reporting ITT analyses and as-treated analyses present a full picture for primary care clinicians and researchers to put findings into context. Next, Orrego et al7 present a cluster randomized trial which evaluates the effectiveness of a virtual community of practice on improving primary health care professionals’ attitudes toward empowering patients with chronic diseases. “Cluster randomizing” is an approach to make a trial more pragmatic in nature. In this approach, participants are randomized at the group level (eg, primary care clinic, health care professionals, etc), which has several benefits, especially when the target of the intervention is at the practice or health system level. Along with logistical conveniences for intervention delivery, a major reason to consider a cluster randomized trial is to avoid contamination bias (eg, intervention is adopted by health care professionals who were randomized to the control arm).8 Instead of randomizing patients to the intervention or control arms, this study randomized 63 primary care practices to study groups. Researchers considering this design should be aware that those benefits must be evaluated against potential limitations, including possible imbalance in clinic/system size, and wide provider and patient EDITORIAL","PeriodicalId":22305,"journal":{"name":"The Annals of Family Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Annals of Family Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1370/afm.2832","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
society, but has also reminded us anew of the limitations and challenges of our scientific approaches. Take the example of randomized trials. While multiple randomized trials were demonstrating the efficacy and safety of SARSCoV-2 vaccines,1 it became clear that other interventions against SARS-CoV-2 (eg, community masking, physical distancing, school closures, national lockdowns, etc) required research paradigms outside of the classic randomized trial design to which many scientists are accustomed.2,3 This again reminds us that randomized trials may have significant practical limitations to their generalizability because they are in tightly controlled settings with narrow eligibility, and therefore often in settings divorced from the real world.4 Whereas classic randomized trials evaluate interventions in ideal settings, pragmatic trials evaluate interventions against real-world alternatives provided in routine care (especially in primary care). Typically, pragmatic trials also relax eligibility criteria which may allow for greater generalizability of study findings. With the benefit of generalizability, however, comes challenges that are unique to pragmatic trials. To balance the relative risks and benefits of both of these designs, investigators employ strategies that often hybridize the 2 designs to maximize benefit and minimize limitation. In this issue, 3 studies demonstrate increasingly used approaches to construct trials that are pragmatic, but retain features and benefits of classic trial design. First, a randomized controlled trial led by Mitchell et al5 sought to evaluate the relative effectiveness of additions to a nationally disseminated readmission reduction program (called Re-Engineered Discharge [RED]) to reduce hospital readmission rates and emergency department visits among depressed patients. In intent-to-treat (ITT) analyses, the study found no difference in all-cause hospitalization between the study arms. Intent-to-treat analyses are used in trials to account for real-word deviation from treatment, and include all randomized study participants in prespecified analyses regardless of events after they are randomized (eg, noncompliance, study withdrawal, protocol deviation, etc). Intent-to-treat analyses are thought to produce less bias than when the randomized participants who were entirely adherent to their assigned intervention are included in this analysis.6 An alternative to an intent-to-treat analysis is to consider as-treated analyses which compares intervention groups that only include patients who actually received the treatment(s) without regard to their randomized assignment.6 In addition to intent-to-treat analyses, Mitchell et al5 also performed as-treated analyses and found that with sufficient uptake of the adapted RED intervention, patients saw a larger decrease in hospital readmission compared with RED alone. While it is tempting to consider the as-treated analysis a definitive analysis, it is known that as-treated analyses are more likely to be biased and exaggerate treatment effects.6 In real-world settings, complete adherence to any intervention is a challenge. Reporting ITT analyses and as-treated analyses present a full picture for primary care clinicians and researchers to put findings into context. Next, Orrego et al7 present a cluster randomized trial which evaluates the effectiveness of a virtual community of practice on improving primary health care professionals’ attitudes toward empowering patients with chronic diseases. “Cluster randomizing” is an approach to make a trial more pragmatic in nature. In this approach, participants are randomized at the group level (eg, primary care clinic, health care professionals, etc), which has several benefits, especially when the target of the intervention is at the practice or health system level. Along with logistical conveniences for intervention delivery, a major reason to consider a cluster randomized trial is to avoid contamination bias (eg, intervention is adopted by health care professionals who were randomized to the control arm).8 Instead of randomizing patients to the intervention or control arms, this study randomized 63 primary care practices to study groups. Researchers considering this design should be aware that those benefits must be evaluated against potential limitations, including possible imbalance in clinic/system size, and wide provider and patient EDITORIAL